Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

44.99USD
17 Nov 2017
Change (% chg)

$0.06 (+0.13%)
Prev Close
$44.93
Open
$44.75
Day's High
$46.98
Day's Low
$44.29
Volume
1,011,924
Avg. Vol
539,261
52-wk High
$46.98
52-wk Low
$11.42

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $7,084.47
Shares Outstanding(Mil.): 157.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage:

Nov 10 2017

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

Nov 07 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Nektar Therapeutics initiates propel clinical study

* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214, a CD122-biased agonist, with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:

Sep 12 2017

BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement

* Nektar Therapeutics - Co, Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:

Aug 25 2017

BRIEF-Nektar Therapeutics Q2 loss per share $0.39

* Nektar therapeutics reports financial results for the second quarter of 2017

Aug 08 2017

BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358

* Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy

Jul 24 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Jul 21 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Jul 21 2017

BRIEF-Nektar presents findings from two phase 1 clinical studies of NKTR-214

* Presented new findings from two phase 1 clinical studies of NKTR-214, nektar's lead immuno-oncology candidate

Jun 05 2017

Competitors

Earnings vs. Estimates